GHRP-6 is a synthetic hexapeptide, His-D-Trp-Ala-Trp-D-Phe-Lys-NH2, and the compound the entire growth hormone secretagogue field was built on. It releases growth hormone through a receptor that is not the GHRH receptor, which is what made it interesting in the first place. That receptor was later cloned and named GHS-R, and its natural ligand was later identified as ghrelin. GHRP-6 also served as the chemical template for the oral non-peptide secretagogues, including MK-677.

What dose of GHRP-6 is used in humans?

The standard human test dose is 1 mcg/kg intravenously, which is roughly 80 mcg for an 80 kg adult. In combined pituitary testing it is paired with 100 mcg of intravenous GHRH, because the two act on different receptors and the response to both together is far larger than to either alone. GHRP-6 is also active subcutaneously, intranasally and orally, with a dose-related response by every route, though non-injected routes require far more peptide for the same effect.

What is GHRP-6 actually used for in medicine?

Pituitary function testing. Its most useful clinical property is not that it releases growth hormone but where it fails to: the response is almost completely absent in pituitary stalk transection and in Cushing syndrome. That makes GHRP-6, alone or combined with GHRH, a practical test for stalk disconnection and a contributor to the workup of adult-onset growth hormone deficiency. It has never been approved as a therapeutic for any indication.

Does GHRP-6 make you hungry?

The hunger effect is the most consistently reported subjective response, and the mechanism is well established in animals: systemic GHRP-6 activates the orexigenic NPY neurons that co-express AgRP in the arcuate nucleus of the hypothalamus. That is the same circuit ghrelin uses. What is thinner than commonly implied is the quantitative human feeding data. Class reviews note an influence on food intake in humans, but controlled measurement of how much extra a person eats after GHRP-6, at what dose, is not a well-populated literature.

Does GHRP-6 work if you are obese?

Yes, and this is one of its more distinctive properties. Growth hormone secretion is markedly suppressed in obesity and most stimulation tests perform poorly there, but GHRP-6 remains a powerful releaser. It also retains its effect in acromegaly, anorexia nervosa and hyperthyroidism. It is blunted in hypothyroidism, where it still substantially outperforms GHRH, and it fails almost entirely in pituitary stalk disconnection and Cushing syndrome.

Is GHRP-6 better than hexarelin or ipamorelin?

For raw growth hormone release per microgram, hexarelin is the more potent of the two hexapeptides. Ipamorelin is the most selective, activating the receptor without the ACTH, cortisol and prolactin spillover the older GHRPs produce. GHRP-6 sits at the other end: it is the least selective and the most orexigenic. Which of those properties counts as better depends entirely on what the compound is for, and none of the three is an approved medicine.

Does GHRP-6 have effects outside the pituitary?

Yes. Receptors for this peptide family are present in heart, adrenal, ovary, testis, lung and skeletal muscle, at densities higher than in the hypothalamic-pituitary system itself, and GHRP-6 displaces the cardiac binding of a labelled hexarelin analogue. There is also a body of Cuban work on GHRP-6 as a cytoprotective agent in ischemia-reperfusion injury and multiple organ failure. That work is real and published, but it is cell culture and rat studies at doses like 120 mcg/kg intraperitoneally, and it has not produced a human therapeutic.

Is GHRP-6 legal to buy?

GHRP-6 is not an approved drug in any major market and is sold only as a research chemical, which means it may not lawfully be sold for human consumption and comes with no assurance of purity, sterility or actual content. Growth hormone secretagogues, GHRP-6 included, are prohibited at all times under section S2 of the WADA Prohibited List, so any drug-tested athlete using it is doping.

GHRP-6: The Peptide That Became a Diagnostic Test

GHRP-6 has a genuine, documented role in human medicine. It is just not the one it gets sold for. The peptide earned its place in endocrinology because of where it stops working: the growth hormone response to GHRP-6 collapses almost completely in pituitary stalk transection and in Cushing syndrome, which turns it into a cheap and informative test of pituitary function. That is the established human use. Everything else attached to the compound is either mechanism, animal work, or extrapolation.

This guide separates those categories rather than blending them, because on GHRP-6 the blending is where most of the misinformation comes from.

What GHRP-6 is and why it mattered

GHRP-6 is a synthetic hexapeptide with the sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH2. It has no structural resemblance to GHRH, the hypothalamic hormone that was supposed to be the only thing that told the pituitary to release growth hormone. And yet it releases growth hormone, powerfully, independently of GHRH and of somatostatin.

That was the finding that opened an entire field. If a small synthetic peptide could do this through a receptor nobody had identified, then there had to be a natural hormone doing the same thing. Roy Smith later described the programme as reverse pharmacology: build molecules that raise growth hormone pulse amplitude, then work backwards to the receptor, then to the ligand. The receptor turned out to be a previously unknown G protein-coupled receptor, expressed mainly in brain, pituitary and pancreas, with no sequence homology to anything then known. The endogenous agonist, found years later, was ghrelin.

Along the way GHRP-6 served as the structural template for the orally active non-peptide secretagogues, L-692,429, L-692,585 and eventually MK-677. Knockout studies in mice later confirmed the whole class are ghrelin mimetics.

So the compound is historically important. Historically important is not the same as therapeutically useful, and GHRP-6 has never been approved for anything. See growth hormone peptides for the wider family.

How it works: four mechanisms at once

Growth hormone pulse amplitude can in principle be raised four ways: increase GHRH release, amplify GHRH signalling at the somatotroph, reduce somatostatin release, or antagonise somatostatin signalling. The striking thing about the GHRPs is that they appear to do all four.

The functional somatostatin antagonism is the piece that explains most of GHRP-6's clinical behaviour. Somatostatin is the brake on growth hormone secretion. A compound that releases the brake produces responses in situations where a compound that only presses the accelerator, like GHRH, does very little.

The site of action is dual, hypothalamic and pituitary. GHRP-6 and GHRH are synergistic when given together, which is why the combined test produces responses several times larger than either agent alone and why stacked GHRH-analogue plus GHRP protocols exist at all. Sermorelin, CJC-1295 and tesamorelin are the GHRH-receptor side of that pairing.

The response is not blocked by opioid receptor antagonists, and it is only blunted, not abolished, by the inhibitory influences that nearly wipe out the GHRH response, including glucose, free fatty acids, glucocorticoids, recombinant growth hormone and exogenous somatostatin. The effect is the same in both sexes. It rises from birth to puberty and declines with age.

The real clinical job: pituitary function testing

GHRP-6 is most useful where it fails. In patients with pituitary stalk transection, the growth hormone response to GHRP-6, and to GHRH plus GHRP-6, is almost completely blocked. Researchers evaluating the peptide as a test of pituitary reserve concluded this made it a cost-effective test for that specific condition. The response is likewise almost absent in Cushing syndrome.

For general growth hormone deficiency the picture is less clean. In short-statured children, the GHRP-6 response was lower in those diagnosed with deficiency than in normal children, but on an individual basis there was considerable overlap between the groups, which limits it as a standalone diagnostic. The combined GHRH plus GHRP-6 test performed better in adult-onset deficiency, and combined testing is where this chemistry actually found a durable clinical foothold.

It is worth stating plainly what this means. The one thing GHRP-6 does in humans that is reproducible, useful and documented across independent groups is diagnose. It is a probe, not a treatment.

The doses used in humans

1 mcg/kg intravenously is the standard human test dose, appearing across independent studies. For an 80 kg adult that is 80 mcg.
100 mcg GHRH intravenously is the usual pairing in the combined test.
Subcutaneous, intranasal and oral routes are all active with a dose-related response, but non-injected routes need substantially more peptide for the same growth hormone release.

Notice that the human test dose is close to what is commonly discussed online, which is unusual for a research peptide. It is also, in the published record, a single acute dose administered under supervision for the purpose of measuring a response, not a repeated regimen intended to produce an outcome. No long-term dosing schedule for GHRP-6 has been validated in humans for any goal, which is a meaningful gap given that hexarelin, its close relative, was taken to sixteen weeks and produced no measurable change in body fat, lean mass or IGF-1.

For the practicalities of handling doses at this scale, see reconstitution, the peptide calculator, and storage.

The hunger effect: strong mechanism, thin human numbers

GHRP-6 is known in practice as the hungry one, and the mechanism behind that reputation is well mapped. Given systemically, it activates the orexigenic NPY neurons that co-express agouti-related peptide in the arcuate nucleus of the hypothalamus. That is precisely the circuit ghrelin uses to drive feeding, which is exactly what you would expect from a ghrelin mimetic.

The mapping work is rodent work. Reviews of the class note an influence on food intake in humans, and appetite stimulation is the most consistently reported subjective effect, but controlled human feeding studies quantifying how much more a person eats after a given dose of GHRP-6 are not a well-populated literature. Figures circulating online for milligram-per-kilogram doses that increased food intake come from animal experiments, and a dose expressed in mg/kg in a mouse should never be read across to a human.

GHRPs have also been shown to accelerate gastric emptying in rats and mice, which is part of why the class was investigated for ileus and for gastrointestinal motility disorders.

Where GHRP-6 works and where it does not

Few compounds have their state dependence documented this thoroughly, and the pattern is more informative than any single number.

Retains its effect in: obesity, where it is a powerful releaser despite the general suppression of growth hormone secretion; acromegaly; anorexia nervosa; hyperthyroidism.

Blunted but still useful in: hypothyroidism. In one comparison, hypothyroid patients had peak growth hormone of 4.1 mcg/L after GHRH against 24.9 in controls, a near-total loss of response. After GHRP-6 the same patients reached 12.6 against 22.1 in controls. The GHRH response was destroyed; the GHRP-6 response was reduced but preserved. Combined, patients reached 52.8 against 77.4 in controls.

Fails almost completely in: pituitary stalk disconnection and Cushing syndrome.

The pattern says the peptide needs an intact hypothalamic-pituitary connection and a normal glucocorticoid environment to do anything. Sever the stalk and it is inert. Flood the system with cortisol and it is inert. That is a real constraint and it rarely appears on pages selling the compound.

The cytoprotection literature, labelled honestly

There is a second research thread on GHRP-6, mostly out of the Center for Genetic Engineering and Biotechnology in Havana, treating it as a tissue-protective agent rather than a growth hormone releaser.

In cell culture, GHRP-6 produced a roughly threefold increase in the migration rate of rat intestinal epithelial and human colonic cancer cell lines without increasing proliferation. In a rat model of multiple organ failure driven by hepatic ischemia and reperfusion, pre-treatment with GHRP-6 at 120 mcg/kg intraperitoneally reduced hepatic and intestinal damage scores, neutrophil infiltration and lipid peroxidation by 50 to 85 percent, with further benefit when combined with epidermal growth factor. Lung and kidney injury were also reduced.

This is legitimate published work and the authors were explicit that further studies appeared justified. It is also cells and rats. Twenty years on it has not produced an approved human therapy, and 120 mcg/kg intraperitoneally in a rat is not a human dose. Anyone citing GHRP-6 for healing or organ protection is citing this literature, usually without saying which species it was done in.

The same caution applies to the receptor distribution data. Binding sites for this peptide family are present in heart, adrenal, ovary, testis, lung and skeletal muscle at densities higher than in the hypothalamic-pituitary system itself, and GHRP-6 displaces the cardiac binding of a labelled hexarelin analogue. Widespread receptors establish the possibility of tissue effects. They do not establish that any of them are beneficial.

Sleep and the rest of the endocrine picture

GHRP-6 increases stage 2 non-REM sleep in humans. That is worth setting against its relatives: ghrelin itself promotes slow-wave sleep, while hexarelin has been shown to reduce stage 4 sleep and EEG delta power when dosed through the evening. Three compounds acting on the same receptor, three different effects on sleep architecture. It is a useful reminder that receptor-level similarity does not predict what a compound does to a person.

On selectivity, GHRP-6 is not clean. The secretagogues as a class have prolactin, ACTH and cortisol-releasing effects alongside growth hormone, and GHRP-6 is among the less selective members. This is the specific problem ipamorelin was designed to solve, and the reason ipamorelin displaced the older GHRPs in most clinical settings. Sermorelin versus ipamorelin and ipamorelin dosing cover the alternative. General class effects are in peptide side effects.

GHRP-6 against the alternatives

Versus hexarelin: one methyl group apart on the second residue. Hexarelin is more potent per microgram and more metabolically stable, and it uniquely binds CD36 in cardiac tissue. GHRP-6 is more orexigenic. Hexarelin has the longer human dosing record, and that record is a null result on body composition.

Versus ipamorelin: ipamorelin trades potency for selectivity, avoiding the ACTH, cortisol and prolactin spillover. For anyone whose interest is a growth hormone pulse without the rest, that is the more sensible member of the family.

Versus MK-677: orally active, long half-life, raises IGF-1 durably, and does not require injection. It also does not bind the cardiac site the peptide GHRPs do, and it brings its own problems with appetite, fluid retention and insulin sensitivity.

Versus GHRH analogues: a different receptor entirely, and synergistic rather than competing. See CJC-1295 with ipamorelin for the standard combined approach, and peptides used in bodybuilding for how these get marketed.

Safety, legality and supply

GHRP-6 is not an approved medicine in the United States or any comparable market. It is sold as a research chemical, which means it may not lawfully be marketed for human consumption, and no regulator has reviewed the manufacturing, purity, sterility or labelling accuracy of any vial on sale. Legal status of research peptides covers this in detail, and FDA-approved peptides lists what has actually cleared review.

Growth hormone secretagogues, GHRP-6 included, are prohibited at all times under section S2 of the WADA Prohibited List. There is no in-competition-only exception. Peptides versus steroids sets out the anti-doping picture.

Acute administration in the study setting has been unremarkable in tolerability terms, which is unsurprising for single supervised doses. What does not exist is any human safety data for repeated GHRP-6 use over months or years. The general concerns that attach to raising growth hormone and IGF-1, for insulin sensitivity and for anyone with an active or suspected malignancy, have not been addressed for this compound because the studies that would address them were never run.

The bottom line

GHRP-6 is a foundational compound with a narrow, real clinical use and a large, mostly preclinical body of everything else. It releases growth hormone reliably, it is a good probe of pituitary integrity, it makes people hungry through a circuit that is well characterised in animals, and it has protective effects in rats that never became a drug.

What it does not have is a single human study showing that repeated dosing produces an outcome anyone would buy it for. Its closest chemical relative does have such a study, ran it for sixteen weeks, and found no change in fat, lean mass, bone density or IGF-1. That absence is the most useful thing to know before deciding what GHRP-6 is worth.